Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00538239 | Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) | PHASE3 | COMPLETED | 711 | — | — | Oct 1, 2007 | Dec 1, 2012 | Feb 13, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| Ridaforolimus | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ridaforolimus | DRUG | Four 10 mg tablets taken by mouth for 5 days per week continuously |
| Placebo | DRUG | Four 10 mg tablets taken by mouth for 5 days per week continuously |
Inclusion Criteria: * Confirmed diagnosis of metastatic soft-tissue or bone sarcoma * Ongoing complete response, partial response, or stable disease (RECIST) after a minimum of 4 cycles (and maximum of 12 months) of any one first, second, or third line of prior cytotoxic chemotherapy for metastatic...